HUMA
$0.78-0.07 (-8.34%)
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
Recent News
Humacyte, Inc. (HUMA) Submits Marketing Authorization Application in Israel for Symvess
Humacyte, Inc. (NASDAQ:HUMA) is one of the 11 Best High Volume Penny Stocks to Buy Now. On March 17, 2026, Humacyte, Inc. (NASDAQ:HUMA) submitted a Marketing Authorization Application to the Israel Ministry of Health for approval of its acellular tissue-engineered vessel, Symvess, for arterial trauma repair. The company is also pursuing a pathway to make […]
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks were softer late Thursday afternoon, with the NYSE Health Care Index decreasing 0
Sector Update: Health Care Stocks Lower in Afternoon Trading
Health care stocks declined Thursday afternoon, with the NYSE Health Care Index down 0.4% and the St
Humacyte Receives $1.5 Million Symvess Purchase Commitment, Launches $20 Million Offering
Humacyte (HUMA) said Thursday that it has received a roughly $1.5 million minimum purchase commitmen
Humacyte, Inc. (HUMA) Is Considered a Good Investment by Brokers: Is That True?
According to the average brokerage recommendation (ABR), one should invest in Humacyte, Inc. (HUMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?